타이샤 젠 테라피 (TSHA) 주가 전망: 목표주가, 배당, 최신 뉴스

Taysha Gene Therapies, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.

The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies, Inc.는 임상 단계의 바이오텍 기업으로, 중추신경계의 중증 단일유전질환 치료를 위해 아데노연관바이러스(AAV) 기반 유전자치료제의 개발 및 상용화에 주력하고 있다. 주요 파이프라인으로는 거대축삭신경병증 치료용 TSHA-120, 렛트 증후군용 TSHA-102, CLN7 질환용 TSHA-121, CLN1 질환용 TSHA-118, SLC13A5 결핍증용 TSHA-105, 타우병증용 TSHA-113, 앵겔만 증후군용 TSHA-106, fragile X 증후군용 TSHA-114 등이 있다.

텍사스대 사우스웨스턴 의학센터(The University of Texas Southwestern Medical Center)와 연구·협력·라이선스 계약을 맺고 있으며, 2019년에 설립되어 본사는 댈러스(텍사스)에 있다.

• 주소: 3000 Pegasus Park Drive, Suite 1430, Dallas, TX 75247, United States

• 전화번호: 214 612 0000

• 웹사이트: https://www.tayshagtx.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 99